Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

AstraZeneca Reiterates Importance Of Salick To Developing Oncology

  • News

Executive Summary

AstraZeneca continues to see long-term value in Salick Health Care from the contact that the treatment clinics provide with current trends in oncology, AstraZeneca CEO Tom McKillop, PhD, said at a 1999 earnings review Feb. 24 in London.

You may also be interested in...



Bristol Exiting Oncology Distribution Business Ahead Of Part B Pinch

Bristol-Myers Squibb has signed an agreement to sell its Oncology Therapeutics Network unit prior to the 2005 reimbursement changes for chemotherapy drugs under the Medicare Rx law

Bristol Exiting Oncology Distribution Business Ahead Of Part B Pinch

Bristol-Myers Squibb has signed an agreement to sell its Oncology Therapeutics Network unit prior to the 2005 reimbursement changes for chemotherapy drugs under the Medicare Rx law

Seroquel, Atacand Lead AstraZeneca New Products; Prilosec Nears $6 Bil.

The anti-psychotic Seroquel is one of the fastest growing products in the AstraZeneca portfolio, with sales totaling $232 mil. in 1999, the company indicated at its 1999 operating results review Feb. 24 in London.

Table

View full table

Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS035685

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By